Drug Trial Radar · NCT00448383
A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Aug 4, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,610
Actual
Start
Sep 2002
Primary completion
Nov 2004
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center study in which adalimumab (D2E7) is administered subcutaneously 40 mg every other week in addition to current anti-rheumatic therapies. Patients must have active disease despite standard anti-rheumatic therapy.
Conditions
- Rheumatoid Arthritis
Interventions
adalimumabBiological
40mg every other week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of disease activity score (DAS28) compared with study entryTime frame: Week 12
- EULAR and ACR response criteria at week 12Time frame: Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.